Atezolizumab
Information
- Drug Name
- Atezolizumab
- Description
- Entry(CIViC)
- 7
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung non-small cell carcinoma | CD274 EXPRESSION CD274 EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 26918451 | Detail |
| lung non-small cell carcinoma | CD274 EXPRESSION CD274 EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 26970723 | Detail |
| cancer | DNMT3A MUTATION DNMT3A MUTATION | B |
Predictive
|
Supports
|
Resistance | Somatic | 2 | 28351930 | Detail |
| lung non-small cell carcinoma | CD274 EXPRESSION CD274 EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 28472902 | Detail |
| lung non-small cell carcinoma | KRAS MUTATION KRAS MUTATION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 28525386 | Detail |
| lung adenocarcinoma | STK11 MUTATION STK11 MUTATION | B |
Predictive
|
Supports
|
Resistance | Somatic | 4 | 29773717 | Detail |
| skin melanoma | HLA-DRA EXPRESSION HLA-DRA EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 26822383 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Meta-Analysis of PD-L1 (CD274) Expression Status i... | CD274 | CD274 EXPRESSION CD274 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| Exploratory biomarker analysis from a phase-II ran... | CD274 | CD274 EXPRESSION CD274 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| A subset of patients receiving PD1/PD-L1 inhibitio... | DNMT3A | DNMT3A MUTATION DNMT3A MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this meta-analysis of 14 studies with 2857 pati... | CD274 | CD274 EXPRESSION CD274 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| A meta-analysis of randomized trials to investigat... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a retrospective analysis in two separate datase... | STK11 | STK11 MUTATION STK11 MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Melanoma patients treated with Anti-PD1 or anti-PD... | HLA-DRA | HLA-DRA EXPRESSION HLA-DRA EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04540211 | Active, not recruiting | Phase 3 | A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma | October 30, 2020 | August 14, 2025 |
| NCT02530489 | Active, not recruiting | Phase 2 | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | February 4, 2016 | December 31, 2025 |
| NCT04300647 | Active, not recruiting | Phase 2 | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer | June 30, 2020 | December 30, 2024 |
| NCT04303858 | Active, not recruiting | Phase 1 | A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors | May 4, 2020 | May 27, 2027 |
| NCT04471428 | Active, not recruiting | Phase 3 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | October 1, 2020 | October 31, 2024 |
| NCT04334941 | Active, not recruiting | Phase 2 | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | July 20, 2020 | November 30, 2025 |
| NCT04338269 | Active, not recruiting | Phase 3 | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment | July 28, 2020 | June 30, 2024 |
| NCT02724878 | Active, not recruiting | Phase 2 | Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma | July 2016 | October 2024 |
| NCT04373369 | Active, not recruiting | Phase 2 | Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | October 7, 2020 | July 5, 2025 |
| NCT02794571 | Active, not recruiting | Phase 1 | Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors | May 23, 2016 | October 5, 2024 |
| NCT04462276 | Active, not recruiting | Phase 2 | Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease | July 28, 2020 | August 2024 |
| NCT04458922 | Active, not recruiting | Phase 2 | Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma | October 5, 2020 | December 13, 2024 |
| NCT04432207 | Active, not recruiting | Phase 1 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer | November 30, 2020 | March 2026 |
| NCT04434040 | Active, not recruiting | Phase 2 | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | July 2, 2020 | December 30, 2027 |
| NCT04446117 | Active, not recruiting | Phase 3 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | June 30, 2020 | August 31, 2024 |
| NCT02839707 | Active, not recruiting | Phase 2/Phase 3 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | June 23, 2017 | September 21, 2024 |
| NCT02844816 | Active, not recruiting | Phase 2 | Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer | March 13, 2017 | September 21, 2024 |
| NCT02849496 | Active, not recruiting | Phase 2 | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer | March 30, 2017 | August 31, 2024 |
| NCT02862275 | Active, not recruiting | Phase 1 | Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | May 24, 2017 | November 21, 2024 |
| NCT02873195 | Active, not recruiting | Phase 2 | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | July 7, 2017 | July 1, 2024 |
| NCT02883062 | Active, not recruiting | Phase 2 | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | August 2, 2017 | January 23, 2025 |
| NCT02908672 | Active, not recruiting | Phase 3 | A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma | January 13, 2017 | May 15, 2024 |
| NCT02912559 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair | October 16, 2017 | April 2, 2025 |
| NCT02935361 | Active, not recruiting | Phase 1/Phase 2 | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | November 2, 2016 | November 30, 2025 |
| NCT02989584 | Active, not recruiting | Phase 1/Phase 2 | A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer | December 20, 2016 | December 2024 |
| NCT06006013 | Active, not recruiting | Phase 2 | Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer | March 5, 2024 | December 16, 2025 |
| NCT05733611 | Active, not recruiting | Phase 2 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | June 29, 2023 | March 1, 2027 |
| NCT03074513 | Active, not recruiting | Phase 2 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | March 3, 2017 | September 30, 2025 |
| NCT03093922 | Active, not recruiting | Phase 2 | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer | March 22, 2017 | March 2025 |
| NCT03125928 | Active, not recruiting | Phase 2 | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | June 13, 2017 | December 2024 |
| NCT03127007 | Active, not recruiting | Phase 1/Phase 2 | Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer | April 27, 2017 | September 2024 |
| NCT05498896 | Active, not recruiting | Phase 2 | Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC | December 19, 2018 | January 30, 2026 |
| NCT03141684 | Active, not recruiting | Phase 2 | Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma | April 25, 2017 | October 31, 2025 |
| NCT05359861 | Active, not recruiting | Phase 2 | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | April 12, 2022 | May 2026 |
| NCT03148418 | Active, not recruiting | Phase 3 | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | September 20, 2017 | March 6, 2030 |
| NCT05334329 | Active, not recruiting | Phase 1 | Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors | July 20, 2022 | September 30, 2025 |
| NCT03170960 | Active, not recruiting | Phase 1/Phase 2 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | September 5, 2017 | August 2024 |
| NCT03174197 | Active, not recruiting | Phase 1/Phase 2 | Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | June 30, 2017 | June 30, 2025 |
| NCT03175432 | Active, not recruiting | Phase 2 | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | June 15, 2017 | June 30, 2026 |
| NCT03179943 | Active, not recruiting | Phase 2 | Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | November 27, 2017 | July 2022 |
| NCT03181100 | Active, not recruiting | Phase 2 | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | July 27, 2017 | July 31, 2025 |
| NCT03193190 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | July 5, 2017 | October 31, 2026 |
| NCT03199885 | Active, not recruiting | Phase 3 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | April 5, 2019 | May 15, 2025 |
| NCT03202316 | Active, not recruiting | Phase 2 | Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer | August 11, 2017 | December 31, 2024 |
| NCT03206047 | Active, not recruiting | Phase 1/Phase 2 | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | November 8, 2017 | March 31, 2025 |
| NCT03206203 | Active, not recruiting | Phase 2 | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | August 29, 2017 | November 15, 2024 |
| NCT03228537 | Active, not recruiting | Phase 1 | Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma | July 16, 2018 | September 21, 2024 |
| NCT03237780 | Active, not recruiting | Phase 2 | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | July 20, 2018 | June 30, 2025 |
| NCT05251948 | Active, not recruiting | Phase 1/Phase 2 | An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma | March 1, 2022 | June 22, 2025 |
| NCT05243862 | Active, not recruiting | Phase 2 | Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | June 2, 2022 | June 2, 2026 |
| NCT05240131 | Active, not recruiting | Phase 1/Phase 2 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | March 15, 2022 | November 1, 2025 |
| NCT03281369 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | October 13, 2017 | April 30, 2025 |
| NCT03281954 | Active, not recruiting | Phase 3 | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | December 19, 2017 | November 30, 2027 |
| NCT03289962 | Active, not recruiting | Phase 1 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | December 21, 2017 | November 1, 2024 |
| NCT05224141 | Active, not recruiting | Phase 3 | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008) | March 24, 2022 | June 7, 2027 |
| NCT03321643 | Active, not recruiting | Phase 1 | Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma | September 18, 2018 | June 30, 2025 |
| NCT03337698 | Active, not recruiting | Phase 1/Phase 2 | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | January 2, 2018 | November 30, 2026 |
| NCT05211323 | Active, not recruiting | Phase 2 | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer | December 7, 2022 | January 31, 2025 |
| NCT05191797 | Active, not recruiting | Phase 1/Phase 2 | Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer | April 11, 2022 | January 15, 2026 |
| NCT03353831 | Active, not recruiting | Phase 3 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | September 11, 2018 | December 1, 2024 |
| NCT05171777 | Active, not recruiting | Phase 2 | A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer | April 4, 2022 | September 20, 2024 |
| NCT03363867 | Active, not recruiting | Phase 2 | BEACON - ABC in Recurrent Platinum Resistant HGSOC | July 10, 2018 | June 30, 2025 |
| NCT05141721 | Active, not recruiting | Phase 2/Phase 3 | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | February 12, 2022 | March 2027 |
| NCT03371017 | Active, not recruiting | Phase 3 | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer | January 11, 2018 | June 30, 2024 |
| NCT03417544 | Active, not recruiting | Phase 2 | Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC | May 21, 2018 | December 2025 |
| NCT05091567 | Active, not recruiting | Phase 3 | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer | November 18, 2021 | March 6, 2026 |
| NCT05009069 | Active, not recruiting | Phase 2 | A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer | March 18, 2022 | October 30, 2026 |
| NCT04984811 | Active, not recruiting | Phase 2 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | November 3, 2021 | March 2025 |
| NCT03463057 | Active, not recruiting | Phase 2 | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL | August 30, 2018 | January 2027 |
| NCT04941287 | Active, not recruiting | Phase 2 | Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | December 15, 2021 | September 1, 2024 |
| NCT03473756 | Active, not recruiting | Phase 1 | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma | May 15, 2018 | August 30, 2024 |
| NCT03483012 | Active, not recruiting | Phase 2 | Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis | May 1, 2018 | September 30, 2025 |
| NCT03498521 | Active, not recruiting | Phase 2 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | July 10, 2018 | June 9, 2024 |
| NCT03502785 | Active, not recruiting | Phase 1/Phase 2 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | May 24, 2018 | December 31, 2024 |
| NCT03513952 | Active, not recruiting | Phase 2 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | June 5, 2019 | October 22, 2024 |
| NCT03526432 | Active, not recruiting | Phase 2 | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | August 8, 2018 | May 2025 |
| NCT03533283 | Active, not recruiting | Phase 1/Phase 2 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | May 8, 2018 | September 30, 2026 |
| NCT03540420 | Active, not recruiting | Phase 2 | Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer | July 31, 2018 | April 2027 |
| NCT04931342 | Active, not recruiting | Phase 2 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | October 7, 2021 | December 31, 2028 |
| NCT03556839 | Active, not recruiting | Phase 3 | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix | September 25, 2018 | November 2024 |
| NCT03563716 | Active, not recruiting | Phase 2 | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | August 10, 2018 | March 31, 2025 |
| NCT03595592 | Active, not recruiting | Phase 3 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | September 7, 2018 | March 15, 2027 |
| NCT03598270 | Active, not recruiting | Phase 3 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer | November 21, 2018 | January 2024 |
| NCT03600701 | Active, not recruiting | Phase 2 | Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | November 29, 2018 | July 17, 2024 |
| NCT03603184 | Active, not recruiting | Phase 3 | Atezolizumab Trial in Endometrial Cancer - AtTEnd | October 2, 2018 | May 2025 |
| NCT03612791 | Active, not recruiting | Phase 2 | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab | August 13, 2018 | April 2025 |
| NCT04832854 | Active, not recruiting | Phase 2 | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer | April 23, 2021 | April 30, 2028 |
| NCT04829383 | Active, not recruiting | Phase 2 | A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma | March 22, 2021 | October 2025 |
| NCT04770896 | Active, not recruiting | Phase 3 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab | April 26, 2021 | July 9, 2025 |
| NCT04751929 | Active, not recruiting | Phase 2 | Abemaciclib With or Without Atezolizumab for mCRPC | August 20, 2021 | December 20, 2025 |
| NCT04740918 | Active, not recruiting | Phase 3 | A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) | June 7, 2021 | April 30, 2024 |
| NCT03697850 | Active, not recruiting | Phase 2 | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy | December 14, 2018 | February 15, 2029 |
| NCT04730999 | Active, not recruiting | Phase 2 | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer | July 1, 2020 | October 17, 2024 |
| NCT03735121 | Active, not recruiting | Phase 3 | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | December 14, 2018 | December 31, 2024 |
| NCT04712643 | Active, not recruiting | Phase 3 | A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma | March 12, 2021 | February 28, 2029 |
| NCT03738228 | Active, not recruiting | Phase 1 | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | January 7, 2019 | September 21, 2024 |
| NCT03755791 | Active, not recruiting | Phase 3 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy | June 10, 2018 | December 1, 2024 |
| NCT03756298 | Active, not recruiting | Phase 2 | Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | January 15, 2019 | January 31, 2027 |
| NCT03762018 | Active, not recruiting | Phase 3 | BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma | April 30, 2019 | June 2024 |
| NCT03775265 | Active, not recruiting | Phase 3 | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | June 3, 2019 | June 1, 2027 |
| NCT03782207 | Active, not recruiting | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice | February 7, 2019 | July 31, 2026 | |
| NCT04710498 | Active, not recruiting | Phase 2 | Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma | June 22, 2021 | November 2024 |
| NCT03799835 | Active, not recruiting | Phase 3 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients | January 17, 2019 | February 1, 2028 |
| NCT03802604 | Active, not recruiting | Early Phase 1 | Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer | December 10, 2018 | April 27, 2025 |
| NCT03811002 | Active, not recruiting | Phase 3 | Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) | July 26, 2019 | December 28, 2026 |
| NCT03818061 | Active, not recruiting | Phase 2 | Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck | March 26, 2019 | March 1, 2024 |
| NCT04665856 | Active, not recruiting | Phase 3 | Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | December 22, 2020 | April 15, 2025 |
| NCT03845166 | Active, not recruiting | Phase 1 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | March 20, 2019 | November 2024 |
| NCT04665843 | Active, not recruiting | Phase 2 | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck | March 2, 2021 | October 2, 2024 |
| NCT04661150 | Active, not recruiting | Phase 2 | A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction | March 12, 2021 | August 30, 2026 |
| NCT04637594 | Active, not recruiting | Phase 3 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | December 10, 2020 | September 2030 |
| NCT03946358 | Active, not recruiting | Phase 2 | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) | February 18, 2020 | October 2025 |
| NCT03961698 | Active, not recruiting | Phase 2 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma | December 17, 2019 | August 31, 2023 |
| NCT04622228 | Active, not recruiting | Phase 2 | Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer | December 16, 2020 | June 30, 2024 |
| NCT04619797 | Active, not recruiting | Phase 2/Phase 3 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer | December 14, 2020 | May 14, 2027 |
| NCT03977194 | Active, not recruiting | Phase 3 | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy | July 23, 2019 | December 2026 |
| NCT03977467 | Active, not recruiting | Phase 2 | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | August 30, 2019 | July 2024 |
| NCT04591431 | Active, not recruiting | Phase 2 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | October 7, 2020 | June 2025 |
| NCT04549428 | Active, not recruiting | Phase 2 | Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC | October 1, 2020 | December 31, 2024 |
| NCT04101357 | Active, not recruiting | Phase 1/Phase 2 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | June 19, 2020 | July 2024 |
| NCT04102098 | Active, not recruiting | Phase 3 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation | December 31, 2019 | July 16, 2027 |
| NCT04543617 | Active, not recruiting | Phase 3 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | September 28, 2020 | March 31, 2027 |
| NCT02486718 | Active, not recruiting | Phase 3 | Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] | October 31, 2015 | August 30, 2035 |
| NCT04134000 | Active, not recruiting | Phase 1 | Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) | February 3, 2020 | September 2024 |
| NCT02500407 | Active, not recruiting | Phase 1/Phase 2 | A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | September 15, 2015 | November 15, 2025 |
| NCT04148911 | Active, not recruiting | Phase 3 | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer | December 17, 2019 | December 15, 2024 |
| NCT04158258 | Active, not recruiting | A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | February 21, 2020 | November 28, 2025 | |
| NCT04161755 | Active, not recruiting | Phase 1 | Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery | December 13, 2019 | November 11, 2024 |
| NCT04194203 | Active, not recruiting | Phase 3 | A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | April 9, 2020 | June 28, 2024 |
| NCT04196530 | Active, not recruiting | Phase 1 | BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab | November 21, 2019 | July 1, 2024 |
| NCT04214418 | Active, not recruiting | Phase 1/Phase 2 | Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies | February 12, 2020 | September 2024 |
| NCT02599454 | Active, not recruiting | Phase 1 | Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | April 26, 2018 | December 2023 |
| NCT04221529 | Active, not recruiting | Phase 2 | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide | January 6, 2020 | October 2024 |
| NCT04245085 | Active, not recruiting | Phase 2 | ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma | September 29, 2020 | December 2024 |
| NCT04513925 | Active, not recruiting | Phase 3 | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) | August 24, 2020 | December 30, 2027 |
| NCT04256421 | Active, not recruiting | Phase 3 | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | February 4, 2020 | April 15, 2026 |
| NCT04262154 | Active, not recruiting | Phase 2 | Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | March 3, 2020 | September 2026 |
| NCT04487067 | Active, not recruiting | Phase 3 | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista | August 25, 2020 | August 13, 2024 |
| NCT04480372 | Active, not recruiting | Phase 2 | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | March 17, 2021 | May 2024 |
| NCT04294810 | Active, not recruiting | Phase 3 | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer | March 4, 2020 | February 21, 2025 |
| NCT03559647 | Completed | The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy | May 30, 2018 | August 20, 2023 | |
| NCT02594384 | Completed | Phase 1 | A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL) | October 2015 | March 30, 2023 |
| NCT03689855 | Completed | Phase 2 | Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC | June 5, 2019 | April 22, 2024 |
| NCT04732286 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy | May 4, 2021 | April 26, 2024 |
| NCT02596971 | Completed | Phase 1/Phase 2 | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) | December 22, 2015 | May 8, 2020 |
| NCT03312530 | Completed | Phase 1/Phase 2 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | November 13, 2017 | May 18, 2021 |
| NCT03694262 | Completed | Phase 2 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | July 19, 2019 | April 5, 2023 |
| NCT03330886 | Completed | A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina | February 9, 2018 | March 2, 2019 | |
| NCT03695380 | Completed | Phase 1 | A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer | January 9, 2019 | July 12, 2023 |
| NCT03201458 | Completed | Phase 2 | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer | February 8, 2018 | February 19, 2024 |
| NCT02174172 | Completed | Phase 1 | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors | August 18, 2014 | November 25, 2019 |
| NCT04857138 | Completed | Phase 1 | A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors | May 18, 2021 | January 18, 2024 |
| NCT05315713 | Completed | Phase 1/Phase 2 | An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma | May 10, 2022 | July 19, 2023 |
| NCT03841110 | Completed | Phase 1 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | February 15, 2019 | November 15, 2022 |
| NCT03232593 | Completed | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | November 29, 2017 | August 12, 2022 | |
| NCT03625141 | Completed | Phase 2 | A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases | December 13, 2018 | April 13, 2023 |
| NCT03256344 | Completed | Phase 1 | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | March 19, 2018 | December 3, 2021 |
| NCT01988896 | Completed | Phase 1 | Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors | December 27, 2013 | November 4, 2019 |
| NCT03264066 | Completed | Phase 2 | A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors | November 23, 2017 | June 25, 2020 |
| NCT03628716 | Completed | Phase 2 | CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | September 18, 2018 | February 2, 2021 |
| NCT03853707 | Completed | Phase 1/Phase 2 | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | March 4, 2019 | September 19, 2023 |
| NCT03276468 | Completed | Phase 2 | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas | February 12, 2018 | August 24, 2022 |
| NCT03866239 | Completed | Phase 1 | A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma | May 7, 2019 | March 13, 2024 |
| NCT02323191 | Completed | Phase 1 | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | January 19, 2015 | August 21, 2020 |
| NCT03285763 | Completed | Phase 4 | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | October 25, 2017 | April 7, 2022 |
| NCT02605915 | Completed | Phase 1 | Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | December 31, 2015 | November 13, 2019 |
| NCT03698461 | Completed | Phase 2 | Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab | May 15, 2019 | October 24, 2023 |
| NCT02220842 | Completed | Phase 1 | A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | December 18, 2014 | January 21, 2020 |
| NCT04028050 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | August 12, 2019 | July 13, 2023 |
| NCT02650713 | Completed | Phase 1 | A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors | January 7, 2016 | January 13, 2020 |
| NCT03359239 | Completed | Phase 1 | Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer | May 8, 2019 | October 12, 2021 |
| NCT02657434 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) | April 30, 2016 | December 13, 2022 |
| NCT03721653 | Completed | Phase 2 | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | November 30, 2018 | August 31, 2023 |
| NCT03726879 | Completed | Phase 3 | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | January 11, 2019 | August 24, 2023 |
| NCT02659384 | Completed | Phase 2 | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer | December 23, 2016 | March 2022 |
| NCT03730012 | Completed | Phase 1/Phase 2 | A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | June 19, 2019 | June 15, 2021 |
| NCT03394885 | Completed | Phase 1/Phase 2 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer | June 19, 2018 | July 20, 2020 |
| NCT01633970 | Completed | Phase 1 | A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | July 11, 2012 | February 26, 2020 |
| NCT04321330 | Completed | Phase 2 | A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma | August 7, 2020 | June 3, 2024 |
| NCT04322643 | Completed | Phase 2 | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | March 23, 2020 | April 17, 2023 |
| NCT03395899 | Completed | Phase 2 | Pre-operative Immunotherapy Combination Strategies in Breast Cancer | December 21, 2017 | August 18, 2023 |
| NCT05116202 | Completed | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | February 2, 2022 | March 27, 2024 |
| NCT02708680 | Completed | Phase 1/Phase 2 | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | May 2016 | March 10, 2021 |
| NCT02715531 | Completed | Phase 1 | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | April 6, 2016 | May 31, 2021 |
| NCT04642365 | Completed | Phase 1 | A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. | January 4, 2021 | January 4, 2024 |
| NCT02008227 | Completed | Phase 3 | A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy | March 11, 2014 | January 9, 2019 |
| NCT02013219 | Completed | Phase 1 | A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) | April 3, 2014 | February 5, 2020 |
| NCT04405349 | Completed | Phase 2 | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | July 1, 2020 | November 24, 2023 |
| NCT04408118 | Completed | Phase 2 | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC | October 5, 2020 | December 7, 2023 |
| NCT03434379 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma | March 15, 2018 | November 17, 2022 |
| NCT04426825 | Completed | Phase 2 | A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer | September 9, 2020 | February 10, 2023 |
| NCT03438318 | Completed | Phase 1 | Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer | March 15, 2018 | December 11, 2019 |
| NCT04584112 | Completed | Phase 1 | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | September 28, 2020 | March 8, 2023 |
| NCT02807636 | Completed | Phase 3 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma | June 30, 2016 | February 12, 2024 |
| NCT04632992 | Completed | Phase 2 | A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | January 13, 2021 | February 27, 2024 |
| NCT02814669 | Completed | Phase 1 | Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor | September 23, 2016 | July 31, 2019 |
| NCT02825940 | Completed | Phase 1 | A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors | August 4, 2016 | November 4, 2022 |
| NCT03922997 | Completed | Phase 3 | A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | July 3, 2019 | August 11, 2022 |
| NCT02350673 | Completed | Phase 1 | A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors | June 29, 2015 | December 16, 2019 |
| NCT01656642 | Completed | Phase 1 | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | August 13, 2012 | March 25, 2020 |
| NCT02848651 | Completed | Phase 2 | A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer | September 23, 2016 | May 14, 2019 |
| NCT03464942 | Completed | Phase 2 | Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer | August 1, 2018 | June 22, 2023 |
| NCT04084951 | Completed | Phase 1 | Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | January 28, 2020 | February 9, 2023 |
| NCT02291289 | Completed | Phase 2 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | April 17, 2015 | March 24, 2021 |
| NCT02876224 | Completed | Phase 1 | Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors | September 30, 2016 | June 25, 2019 |
| NCT02876510 | Completed | Phase 1 | ACTolog in Patients With Solid Cancers | June 30, 2017 | September 22, 2021 |
| NCT02892318 | Completed | Phase 1 | A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) | October 31, 2016 | December 12, 2019 |
| NCT02902029 | Completed | Phase 2 | Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | November 2016 | March 2024 |
| NCT04939480 | Completed | Phase 2 | Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN | October 6, 2021 | March 14, 2024 |
| NCT04631029 | Completed | Phase 1 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | April 27, 2021 | July 11, 2023 |
| NCT02921269 | Completed | Phase 2 | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer | March 10, 2017 | January 13, 2021 |
| NCT02924883 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy | September 26, 2016 | February 6, 2020 |
| NCT02926833 | Completed | Phase 1/Phase 2 | Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | September 29, 2016 | January 12, 2023 |
| NCT02928406 | Completed | Phase 3 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | November 30, 2016 | December 12, 2022 |
| NCT03498716 | Completed | Phase 3 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer | August 2, 2018 | August 14, 2023 |
| NCT02951767 | Completed | Phase 2 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | May 31, 2014 | February 28, 2023 |
| NCT04091217 | Completed | Phase 2 | Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma | November 25, 2019 | September 1, 2023 |
| NCT02994576 | Completed | Phase 2 | Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer | December 12, 2016 | March 2023 |
| NCT01375842 | Completed | Phase 1 | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors | June 21, 2011 | September 30, 2018 |
| NCT03014648 | Completed | Phase 2 | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | July 18, 2017 | March 31, 2022 |
| NCT03016312 | Completed | Phase 3 | A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen | January 10, 2017 | December 20, 2022 |
| NCT03023423 | Completed | Phase 1/Phase 2 | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer | December 23, 2016 | September 26, 2019 |
| NCT06049966 | Completed | Phase 1 | Atezolizumab in Large Cell Neuroendocrine Carcinoma | March 1, 2018 | May 1, 2023 |
| NCT03038100 | Completed | Phase 3 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 8, 2017 | August 12, 2022 |
| NCT02451423 | Completed | Phase 2 | Neoadjuvant Atezolizumab in Localized Bladder Cancer | March 29, 2016 | March 31, 2023 |
| NCT03059667 | Completed | Phase 2 | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | March 13, 2017 | December 1, 2020 |
| NCT03063762 | Completed | Phase 1 | Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) | March 20, 2017 | June 14, 2021 |
| NCT03073525 | Completed | Phase 2 | A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | May 31, 2017 | May 18, 2022 |
| NCT03526900 | Completed | Phase 2 | Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis | July 7, 2018 | September 15, 2022 |
| NCT03087864 | Completed | Phase 2 | PDL-1 Targeting in Resectable Oesophageal Cancer | June 28, 2017 | July 1, 2019 |
| NCT02471846 | Completed | Phase 1 | A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | July 28, 2015 | October 2, 2019 |
| NCT03101280 | Completed | Phase 1 | A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer | April 27, 2017 | August 11, 2020 |
| NCT03102242 | Completed | Phase 2 | Atezolizumab Immunotherapy in Patients With Advanced NSCLC | November 1, 2017 | October 1, 2022 |
| NCT03108131 | Completed | Phase 2 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | April 7, 2017 | April 2, 2024 |
| NCT03800836 | Completed | Phase 1 | A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | February 13, 2018 | March 15, 2022 |
| NCT02031458 | Completed | Phase 2 | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | January 22, 2014 | January 11, 2019 |
| NCT02091141 | Completed | Phase 2 | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | April 14, 2014 | May 24, 2023 |
| NCT03801304 | Completed | Phase 2 | Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer | January 24, 2019 | February 23, 2022 |
| NCT03976518 | Completed | Phase 2 | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) | May 7, 2019 | February 12, 2024 |
| NCT02508870 | Completed | Phase 1 | A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes | September 30, 2015 | June 10, 2019 |
| NCT03158389 | Completed | Phase 1/Phase 2 | NCT Neuro Master Match - N²M² (NOA-20) | May 7, 2018 | February 22, 2023 |
| NCT03164993 | Completed | Phase 2 | Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer | June 1, 2017 | September 30, 2023 |
| NCT04920981 | Completed | Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC | February 2, 2021 | November 24, 2021 | |
| NCT02108652 | Completed | Phase 2 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) | May 31, 2014 | February 28, 2023 |
| NCT04123470 | Completed | Phase 1/Phase 2 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | January 28, 2020 | July 30, 2023 |
| NCT01903993 | Completed | Phase 2 | A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" | August 6, 2013 | September 6, 2018 |
| NCT03178851 | Completed | Phase 1 | Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma | June 20, 2017 | September 21, 2020 |
| NCT04677504 | Completed | Phase 2 | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | February 23, 2021 | August 25, 2023 |
| NCT02304393 | Completed | Phase 1 | A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors | December 12, 2014 | November 7, 2019 |
| NCT04177108 | Completed | Phase 3 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | November 25, 2019 | February 28, 2023 |
| NCT04869501 | No longer available | Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer | |||
| NCT05733598 | Not yet recruiting | Phase 2 | RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC | April 1, 2024 | July 1, 2027 |
| NCT06294548 | Not yet recruiting | Phase 1/Phase 2 | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | October 31, 2024 | May 28, 2028 |
| NCT06012734 | Not yet recruiting | Phase 1 | LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients | December 2023 | July 2026 |
| NCT06416436 | Not yet recruiting | Phase 1 | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | May 23, 2024 | July 1, 2027 |
| NCT06439485 | Not yet recruiting | Phase 2 | Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion | November 29, 2024 | February 22, 2030 |
| NCT06066138 | Not yet recruiting | Phase 1 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | June 23, 2024 | November 29, 2026 |
| NCT05703997 | Not yet recruiting | Phase 2 | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction | January 2023 | January 2029 |
| NCT05859217 | Not yet recruiting | Phase 2 | A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) | December 2024 | June 2028 |
| NCT06287775 | Not yet recruiting | Phase 1/Phase 2 | Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | June 28, 2024 | January 31, 2026 |
| NCT05096715 | Not yet recruiting | Phase 1 | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | January 2022 | January 1, 2026 |
| NCT06339424 | Not yet recruiting | Phase 2 | Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma | March 29, 2024 | March 30, 2031 |
| NCT06161532 | Not yet recruiting | Phase 2 | Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer | June 23, 2024 | November 1, 2028 |
| NCT06302426 | Not yet recruiting | Phase 1 | Trial of INI-4001 in Patients With Advanced Solid Tumours | March 29, 2024 | April 30, 2026 |
| NCT06328036 | Not yet recruiting | Phase 2 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma | June 21, 2024 | July 1, 2025 |
| NCT06362252 | Not yet recruiting | Phase 1/Phase 2 | A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | June 17, 2024 | December 30, 2026 |
| NCT05542407 | Recruiting | Phase 1 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | August 16, 2023 | January 15, 2025 |
| NCT01810913 | Recruiting | Phase 2/Phase 3 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | March 22, 2013 | January 1, 2027 |
| NCT02705196 | Recruiting | Phase 1/Phase 2 | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | November 2016 | October 2025 |
| NCT02846623 | Recruiting | Phase 2 | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | January 31, 2017 | February 28, 2025 |
| NCT02997228 | Recruiting | Phase 3 | Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study | January 19, 2018 | November 30, 2024 |
| NCT03178552 | Recruiting | Phase 2/Phase 3 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | September 22, 2017 | August 3, 2028 |
| NCT03262454 | Recruiting | Phase 2 | Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC | January 22, 2018 | July 31, 2024 |
| NCT03421288 | Recruiting | Phase 2 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness | September 14, 2018 | December 31, 2027 |
| NCT03424005 | Recruiting | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | April 2, 2018 | May 3, 2026 |
| NCT03548428 | Recruiting | Phase 2 | Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) | June 4, 2020 | December 1, 2027 |
| NCT03554083 | Recruiting | Phase 2 | Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma | October 5, 2018 | June 29, 2025 |
| NCT03568656 | Recruiting | Phase 1/Phase 2 | Study to Evaluate CCS1477 in Advanced Tumours | July 23, 2018 | March 2024 |
| NCT03614949 | Recruiting | Phase 2 | SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer | January 29, 2019 | October 2025 |
| NCT03708224 | Recruiting | Phase 2 | Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | March 8, 2019 | June 30, 2027 |
| NCT03767075 | Recruiting | Phase 2 | A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | December 10, 2018 | November 2026 |
| NCT03768063 | Recruiting | Phase 3 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | February 28, 2019 | July 5, 2028 |
| NCT03784326 | Recruiting | Phase 2 | Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma | February 19, 2019 | December 31, 2024 |
| NCT03821246 | Recruiting | Phase 2 | Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | October 30, 2019 | February 28, 2025 |
| NCT03830918 | Recruiting | Phase 1/Phase 2 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | March 6, 2019 | January 3, 2026 |
| NCT03869190 | Recruiting | Phase 1/Phase 2 | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | June 1, 2019 | November 27, 2027 |
| NCT03942328 | Recruiting | Phase 1/Phase 2 | Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer | September 19, 2019 | February 29, 2028 |
| NCT04017455 | Recruiting | Phase 2 | Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN) | October 22, 2019 | August 30, 2024 |
| NCT04020809 | Recruiting | Phase 1 | Neoadjuvant Atezolizumab in Cutaneous Melanoma | September 25, 2020 | December 2025 |
| NCT04096638 | Recruiting | Phase 1 | Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | September 23, 2019 | March 2027 |
| NCT04107168 | Recruiting | Microbiome Immunotherapy Toxicity and Response Evaluation | July 8, 2020 | July 8, 2025 | |
| NCT04109456 | Recruiting | Phase 1 | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | March 16, 2020 | September 30, 2024 |
| NCT04138628 | Recruiting | Phase 2 | Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy | March 24, 2020 | November 1, 2029 |
| NCT04166721 | Recruiting | Phase 1/Phase 2 | WaKING: Wnt and checKpoint INhibition in Gastric Cancer | February 11, 2020 | September 11, 2025 |
| NCT04180072 | Recruiting | N/A | Atezolizumab Plus Bevacizumab With HCC and HBV Infection | March 12, 2020 | December 31, 2025 |
| NCT04185831 | Recruiting | Phase 2 | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial | October 20, 2020 | October 2024 |
| NCT04185883 | Recruiting | Phase 1 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | December 17, 2019 | December 31, 2027 |
| NCT04214262 | Recruiting | Phase 3 | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer | August 13, 2020 | May 1, 2028 |
| NCT04216953 | Recruiting | Phase 1/Phase 2 | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma | February 12, 2020 | February 1, 2027 |
| NCT04250155 | Recruiting | Phase 1 | An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | March 9, 2020 | September 14, 2025 |
| NCT04253145 | Recruiting | Phase 1/Phase 2 | Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. | December 13, 2019 | May 2025 |
| NCT04273061 | Recruiting | Phase 2 | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity | June 17, 2020 | October 2026 |
| NCT04289779 | Recruiting | Phase 2 | Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer | May 21, 2020 | May 2025 |
| NCT04302025 | Recruiting | Phase 2 | A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer | November 6, 2020 | March 6, 2029 |
| NCT04310020 | Recruiting | Phase 2 | Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | January 13, 2021 | September 1, 2024 |
| NCT04341181 | Recruiting | Phase 2 | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | August 24, 2020 | April 30, 2025 |
| NCT04356729 | Recruiting | Phase 2 | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | August 6, 2020 | September 1, 2025 |
| NCT04367311 | Recruiting | Phase 2 | Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) | May 22, 2020 | January 2025 |
| NCT04387084 | Recruiting | Phase 1 | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | August 12, 2020 | August 12, 2025 |
| NCT04402788 | Recruiting | Phase 2/Phase 3 | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | January 7, 2021 | April 30, 2027 |
| NCT04440735 | Recruiting | Phase 1/Phase 2 | A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors | October 7, 2020 | December 2024 |
| NCT04449874 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | July 29, 2020 | November 30, 2024 |
| NCT04802759 | Recruiting | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | June 20, 2021 | October 31, 2026 |
| NCT04803994 | Recruiting | Phase 3 | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | July 6, 2021 | April 1, 2025 |
| NCT04812366 | Recruiting | Phase 2 | Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer | September 21, 2021 | April 1, 2026 |
| NCT04817956 | Recruiting | Phase 2 | Improving Public Cancer Care by Implementing Precision Medicine in Norway | April 1, 2021 | April 30, 2045 |
| NCT04857684 | Recruiting | Early Phase 1 | SBRT + Atezolizumab + Bevacizumab in Resectable HCC | June 18, 2021 | December 31, 2025 |
| NCT04873362 | Recruiting | Phase 3 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | May 4, 2021 | October 2, 2034 |
| NCT04896697 | Recruiting | Phase 1/Phase 2 | XTX101 Monotherapy and XTX101 and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors | September 13, 2021 | March 30, 2026 |
| NCT04902040 | Recruiting | Phase 1/Phase 2 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | April 14, 2021 | June 1, 2025 |
| NCT04919369 | Recruiting | Phase 1 | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | October 18, 2021 | December 31, 2024 |
| NCT04919382 | Recruiting | Phase 2 | Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | January 26, 2022 | December 31, 2025 |
| NCT04923776 | Recruiting | Phase 2 | Liver Directed RT + Chemo-immunotherapy for ES-SCLC | September 20, 2021 | February 2025 |
| NCT04929223 | Recruiting | Phase 1 | A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | October 22, 2021 | April 15, 2026 |
| NCT04958811 | Recruiting | Phase 2 | Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC | December 21, 2021 | December 2024 |
| NCT04981509 | Recruiting | Phase 2 | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | June 10, 2022 | December 31, 2024 |
| NCT05000294 | Recruiting | Phase 1/Phase 2 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | December 7, 2021 | December 2025 |
| NCT05001880 | Recruiting | Phase 2 | Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma | March 22, 2022 | August 20, 2025 |
| NCT05022927 | Recruiting | Phase 1 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | June 1, 2021 | December 31, 2025 |
| NCT05038657 | Recruiting | Phase 2 | Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC). | May 30, 2022 | January 2025 |
| NCT05039281 | Recruiting | Phase 1/Phase 2 | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | September 23, 2022 | December 31, 2025 |
| NCT05047250 | Recruiting | Phase 3 | A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer | June 14, 2022 | August 31, 2027 |
| NCT05058651 | Recruiting | Phase 2/Phase 3 | Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung | June 28, 2022 | October 1, 2028 |
| NCT05063552 | Recruiting | Phase 2/Phase 3 | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | March 13, 2023 | December 15, 2027 |
| NCT05085496 | Recruiting | Phase 1 | Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC | April 19, 2022 | December 1, 2024 |
| NCT05092373 | Recruiting | Phase 1 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | April 29, 2022 | September 1, 2026 |
| NCT05097911 | Recruiting | Phase 1 | Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. | August 2, 2021 | April 2027 |
| NCT05112965 | Recruiting | Phase 3 | An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | December 1, 2021 | December 31, 2025 |
| NCT05118724 | Recruiting | Phase 2 | Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin | December 10, 2021 | November 15, 2026 |
| NCT05142696 | Recruiting | Phase 1/Phase 2 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | July 13, 2022 | May 3, 2028 |
| NCT05159245 | Recruiting | Phase 2 | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | December 10, 2021 | November 25, 2026 |
| NCT05168163 | Recruiting | Phase 2 | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | May 27, 2022 | December 31, 2026 |
| NCT05168618 | Recruiting | Phase 2 | Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial | March 11, 2022 | January 2027 |
| NCT05174650 | Recruiting | Phase 2 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | April 20, 2022 | August 2026 |
| NCT05185505 | Recruiting | Phase 4 | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | January 30, 2023 | October 31, 2027 |
| NCT05286801 | Recruiting | Phase 1/Phase 2 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | November 17, 2022 | September 30, 2025 |
| NCT05295212 | Recruiting | Phase 2 | Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB | February 1, 2023 | July 1, 2024 |
| NCT05300282 | Recruiting | Phase 1/Phase 2 | Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients | August 3, 2022 | December 8, 2028 |
| NCT05312671 | Recruiting | Phase 2 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | June 27, 2022 | June 2027 |
| NCT05333458 | Recruiting | Phase 2 | Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study | August 29, 2022 | May 1, 2025 |
| NCT05361395 | Recruiting | Phase 1 | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | August 24, 2022 | January 1, 2027 |
| NCT05394337 | Recruiting | Phase 1/Phase 2 | Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma | February 23, 2023 | July 31, 2024 |
| NCT05411081 | Recruiting | Phase 2 | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial | March 24, 2023 | July 1, 2027 |
| NCT05425940 | Recruiting | Phase 3 | Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer | September 7, 2022 | February 2026 |
| NCT05440708 | Recruiting | Phase 1/Phase 2 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | March 23, 2023 | March 2025 |
| NCT05450562 | Recruiting | Phase 1/Phase 2 | Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors | September 20, 2022 | December 12, 2030 |
| NCT05459129 | Recruiting | Phase 1/Phase 2 | A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) | April 13, 2023 | August 11, 2024 |
| NCT05468359 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | November 7, 2022 | June 2037 |
| NCT05470595 | Recruiting | Phase 2 | A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung | January 18, 2022 | January 31, 2029 |
| NCT05482516 | Recruiting | Phase 3 | Evaluating Novel Therapies in ctDNA Positive GI Cancers | March 29, 2023 | December 2028 |
| NCT05487235 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | August 17, 2022 | May 31, 2025 |
| NCT05515627 | Recruiting | Phase 1 | Atezolizumab for Idiopathic Pulmonary Fibrosis | February 15, 2023 | April 30, 2026 |
| NCT05525858 | Recruiting | KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | September 28, 2022 | September 2025 | |
| NCT05528952 | Recruiting | Phase 2 | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma | September 27, 2022 | September 30, 2027 |
| NCT05538091 | Recruiting | Phase 2 | Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | May 15, 2023 | April 1, 2028 |
| NCT00781612 | Recruiting | Phase 2 | A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | October 16, 2008 | September 20, 2029 |
| NCT05546879 | Recruiting | Phase 1 | Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC | March 15, 2023 | November 15, 2025 |
| NCT05581004 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | October 20, 2022 | October 31, 2025 |
| NCT05595460 | Recruiting | Phase 1 | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | October 10, 2022 | December 2026 |
| NCT05645692 | Recruiting | Phase 2 | A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer | April 13, 2023 | December 30, 2026 |
| NCT05681039 | Recruiting | Phase 2 | Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). | June 2, 2023 | November 1, 2026 |
| NCT05689671 | Recruiting | Phase 4 | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma | December 6, 2023 | October 2026 |
| NCT05703971 | Recruiting | Phase 1/Phase 2 | Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | May 9, 2024 | August 2027 |
| NCT05715281 | Recruiting | Phase 2 | Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial | September 26, 2023 | October 15, 2026 |
| NCT05717400 | Recruiting | Phase 4 | Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy | February 7, 2023 | October 31, 2026 |
| NCT05722886 | Recruiting | Phase 2/Phase 3 | DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol | March 1, 2023 | October 2029 |
| NCT05746481 | Recruiting | Phase 2 | Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases | August 8, 2023 | April 30, 2027 |
| NCT05765084 | Recruiting | Phase 1/Phase 2 | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma | February 24, 2023 | October 2026 |
| NCT05770102 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | October 25, 2023 | October 2029 |
| NCT05781308 | Recruiting | Phase 2 | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | April 26, 2023 | June 2026 |
| NCT05797493 | Recruiting | Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer | October 4, 2022 | June 2027 | |
| NCT05798663 | Recruiting | Phase 2 | Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC | December 7, 2023 | October 2027 |
| NCT05825625 | Recruiting | Phase 2 | NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | May 26, 2023 | February 1, 2030 |
| NCT05834348 | Recruiting | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | June 26, 2023 | February 3, 2025 | |
| NCT05836584 | Recruiting | Phase 2 | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | December 6, 2023 | October 31, 2027 |
| NCT05844150 | Recruiting | Phase 2/Phase 3 | A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC | June 1, 2023 | December 2025 |
| NCT05862285 | Recruiting | Phase 3 | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | June 1, 2023 | March 1, 2033 |
| NCT05867121 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | October 2, 2023 | December 30, 2025 |
| NCT05886465 | Recruiting | Phase 2 | HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial | May 24, 2023 | December 1, 2024 |
| NCT05904886 | Recruiting | Phase 3 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) | September 14, 2023 | September 1, 2026 |
| NCT05907980 | Recruiting | Phase 1 | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | May 24, 2023 | December 31, 2026 |
| NCT05908786 | Recruiting | Phase 1/Phase 2 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | December 5, 2023 | September 30, 2028 |
| NCT05968326 | Recruiting | Phase 2 | A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma | October 18, 2023 | December 27, 2029 |
| NCT05999812 | Recruiting | Phase 2 | Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer | December 19, 2023 | October 1, 2028 |
| NCT06003621 | Recruiting | Phase 2 | Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients | December 15, 2023 | November 1, 2028 |
| NCT06031233 | Recruiting | Phase 4 | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | September 1, 2023 | December 2024 |
| NCT06031441 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | November 27, 2023 | December 31, 2026 |
| NCT06043674 | Recruiting | Phase 2 | A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation | January 22, 2024 | January 15, 2033 |
| NCT06069726 | Recruiting | Phase 2 | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial | March 21, 2024 | January 1, 2027 |
| NCT06077500 | Recruiting | Phase 1 | DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer | January 11, 2024 | June 25, 2026 |
| NCT06096779 | Recruiting | Phase 2 | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis | May 31, 2024 | November 16, 2026 |
| NCT06109272 | Recruiting | Phase 2/Phase 3 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | January 11, 2024 | September 6, 2030 |
| NCT06110572 | Recruiting | Phase 1/Phase 2 | Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation | July 31, 2024 | June 30, 2028 |
| NCT06117891 | Recruiting | An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery | November 27, 2023 | February 1, 2027 | |
| NCT06133062 | Recruiting | Phase 2 | Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma | November 16, 2023 | September 30, 2030 |
| NCT06254911 | Recruiting | Phase 2 | Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma | October 27, 2023 | August 4, 2026 |
| NCT06267001 | Recruiting | Phase 3 | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy | March 21, 2024 | June 30, 2039 |
| NCT06323382 | Recruiting | Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma | January 1, 2021 | December 30, 2024 | |
| NCT06331598 | Recruiting | Phase 2 | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) | July 30, 2024 | September 20, 2029 |
| NCT06342037 | Recruiting | Phase 2 | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial | June 12, 2024 | April 1, 2030 |
| NCT06390059 | Recruiting | Phase 2 | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | August 28, 2023 | August 2026 |
| NCT04467723 | Recruiting | Phase 1/Phase 2 | Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC | May 18, 2022 | August 2025 |
| NCT04471727 | Recruiting | Phase 1/Phase 2 | Study in Patients With Advanced Cancers Associated With Expression of DLL3 | December 29, 2020 | December 2025 |
| NCT04477759 | Recruiting | Phase 1 | Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer | January 26, 2021 | December 30, 2025 |
| NCT04512430 | Recruiting | Phase 2 | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | December 2, 2020 | December 30, 2025 |
| NCT04524871 | Recruiting | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | November 2, 2020 | August 31, 2026 |
| NCT04551521 | Recruiting | Phase 2 | CRAFT: The NCT-PMO-1602 Phase II Trial | October 13, 2021 | June 30, 2025 |
| NCT04560972 | Recruiting | Phase 1 | LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | May 28, 2021 | March 9, 2026 |
| NCT04563338 | Recruiting | Phase 2 | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | June 4, 2021 | December 5, 2024 |
| NCT04589845 | Recruiting | Phase 2 | Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | January 18, 2021 | September 25, 2032 |
| NCT04624399 | Recruiting | Phase 2 | Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer | July 13, 2021 | December 1, 2024 |
| NCT04630730 | Recruiting | Phase 2 | Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | June 24, 2022 | June 2030 |
| NCT04649489 | Recruiting | A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev | April 19, 2021 | March 31, 2028 | |
| NCT04659382 | Recruiting | Phase 2 | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | October 7, 2020 | October 31, 2024 |
| NCT04660344 | Recruiting | Phase 3 | A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy | May 3, 2021 | April 1, 2031 |
| NCT04691817 | Recruiting | Phase 1/Phase 2 | Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | July 25, 2023 | September 2026 |
| NCT04696575 | Recruiting | Phase 2 | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | July 2, 2021 | July 1, 2026 |
| NCT04721132 | Recruiting | Phase 2 | Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | February 10, 2021 | December 31, 2027 |
| NCT04729959 | Recruiting | Phase 2 | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | March 11, 2022 | June 1, 2025 |
| NCT04739670 | Recruiting | Phase 2 | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer | March 1, 2021 | September 30, 2025 |
| NCT04776447 | Recruiting | Phase 2 | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) | June 16, 2021 | November 15, 2027 |
| NCT04796012 | Recruiting | Phase 1/Phase 2 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | April 18, 2023 | January 2025 |
| NCT03024437 | Suspended | Phase 1/Phase 2 | Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma | June 29, 2017 | June 30, 2024 |
| NCT05053737 | Suspended | Phase 1 | Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC | November 2, 2021 | November 2024 |
| NCT05501665 | Suspended | Phase 1/Phase 2 | Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | May 9, 2023 | February 1, 2027 |
| NCT04276376 | Suspended | Phase 2 | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors | April 12, 2019 | April 2025 |
| NCT05019703 | Suspended | Phase 2 | Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study | April 25, 2023 | December 31, 2027 |
| NCT03422523 | Terminated | Phase 2 | Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy | May 9, 2018 | November 18, 2021 |
| NCT02541604 | Terminated | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | November 30, 2015 | June 6, 2019 |
| NCT05110781 | Terminated | Phase 2 | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site | December 7, 2021 | April 18, 2023 |
| NCT04167137 | Terminated | Phase 1 | Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants | December 12, 2019 | December 9, 2021 |
| NCT04541173 | Terminated | Phase 2 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | November 30, 2020 | June 30, 2023 |
| NCT04102618 | Terminated | Early Phase 1 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | March 29, 2019 | April 20, 2022 |
| NCT04099836 | Terminated | Phase 2 | Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib | July 9, 2020 | June 15, 2023 |
| NCT03138889 | Terminated | Phase 1/Phase 2 | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | June 9, 2017 | August 24, 2022 |
| NCT03399643 | Terminated | A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce) | December 28, 2017 | January 28, 2019 | |
| NCT04422210 | Terminated | Phase 1 | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). | September 22, 2020 | November 6, 2020 |
| NCT04404140 | Terminated | Phase 1 | A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). | July 9, 2020 | October 14, 2022 |
| NCT04471415 | Terminated | Phase 1/Phase 2 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | August 31, 2020 | March 28, 2023 |
| NCT04308785 | Terminated | Phase 2 | A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer | December 1, 2021 | July 25, 2023 |
| NCT05093608 | Terminated | Phase 1 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | November 3, 2021 | October 12, 2022 |
| NCT03273153 | Terminated | Phase 3 | A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma | December 11, 2017 | February 19, 2021 |
| NCT04801966 | Terminated | N/A | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | September 23, 2021 | December 30, 2022 |
| NCT03272217 | Terminated | Phase 2 | Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | September 13, 2017 | March 17, 2022 |
| NCT03267940 | Terminated | Phase 1 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | October 2, 2017 | November 11, 2019 |
| NCT02298153 | Terminated | Phase 1 | A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110) | November 2014 | November 8, 2017 |
| NCT03637764 | Terminated | Phase 1/Phase 2 | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | August 6, 2018 | May 11, 2022 |
| NCT03618953 | Terminated | Phase 1 | This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers | June 21, 2018 | March 5, 2021 |
| NCT02919449 | Terminated | Phase 1 | Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab | August 3, 2017 | January 19, 2018 |
| NCT02409355 | Terminated | Phase 3 | A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | May 7, 2015 | December 7, 2017 |
| NCT03208712 | Terminated | Early Phase 1 | Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy | November 1, 2017 | August 2, 2018 |
| NCT03041311 | Terminated | Phase 2 | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC | June 29, 2017 | October 29, 2020 |
| NCT03154827 | Terminated | Phase 1/Phase 2 | A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study | January 8, 2018 | April 1, 2020 |
| NCT03566485 | Terminated | Phase 1/Phase 2 | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer | July 10, 2018 | December 10, 2020 |
| NCT03147040 | Terminated | Phase 2 | AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer | November 2, 2017 | July 1, 2022 |
| NCT03555149 | Terminated | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | September 27, 2018 | September 26, 2022 |
| NCT04933227 | Terminated | Phase 2 | A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) | August 6, 2021 | November 17, 2023 |
| NCT03465891 | Terminated | Phase 2 | Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma | March 9, 2018 | December 17, 2019 |
| NCT02982694 | Terminated | Phase 2 | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | November 24, 2017 | November 27, 2020 |
| NCT05395052 | Terminated | Phase 1 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | May 31, 2022 | August 11, 2023 |
| NCT03455556 | Terminated | Phase 1 | Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer | August 10, 2018 | January 7, 2020 |
| NCT02303951 | Terminated | Phase 2 | Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC | January 22, 2015 | May 14, 2020 |
| NCT03120676 | Terminated | Phase 2 | Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma | April 14, 2017 | November 12, 2018 |
| NCT03452137 | Terminated | Phase 3 | A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck | April 3, 2018 | March 6, 2024 |
| NCT02792192 | Terminated | Phase 1/Phase 2 | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants | June 13, 2016 | September 29, 2020 |
| NCT05448677 | Terminated | Phase 2 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma | December 15, 2022 | March 8, 2024 |
| NCT05456165 | Terminated | Phase 2 | Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer | May 19, 2022 | September 1, 2022 |
| NCT02609984 | Terminated | Phase 2 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | April 29, 2015 | February 6, 2019 |
| NCT05060003 | Terminated | Phase 2 | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection | November 8, 2022 | November 27, 2023 |
| NCT03115801 | Terminated | Phase 2 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | November 2016 | October 13, 2020 |
| NCT03050060 | Terminated | Phase 2 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | June 9, 2017 | July 12, 2020 |
| NCT04045028 | Terminated | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | July 22, 2019 | March 28, 2023 |
| NCT03979066 | Terminated | Phase 2 | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma | November 1, 2019 | November 3, 2019 |
| NCT04610684 | Terminated | Phase 2 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | January 5, 2021 | September 20, 2022 |
| NCT03973333 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab | May 17, 2019 | September 25, 2023 |
| NCT02322814 | Terminated | Phase 2 | A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread | March 12, 2015 | September 17, 2021 |
| NCT03952325 | Terminated | Phase 2 | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | July 9, 2019 | June 23, 2021 |
| NCT03922477 | Terminated | Phase 1 | A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | October 8, 2019 | November 3, 2020 |
| NCT03901573 | Terminated | Phase 1/Phase 2 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | December 26, 2019 | August 15, 2023 |
| NCT04639245 | Terminated | Phase 1/Phase 2 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | July 19, 2021 | August 16, 2022 |
| NCT02450331 | Terminated | Phase 3 | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection | October 5, 2015 | June 14, 2022 |
| NCT03029832 | Terminated | Phase 2 | A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy | April 27, 2017 | April 25, 2018 |
| NCT03357224 | Terminated | Phase 2 | PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) | September 24, 2018 | August 18, 2022 |
| NCT03894007 | Terminated | Phase 2 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | May 23, 2019 | June 30, 2021 |
| NCT03892525 | Terminated | Phase 1 | Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma | July 4, 2019 | April 7, 2021 |
| NCT04690855 | Terminated | Phase 2 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | October 4, 2021 | December 20, 2022 |
| NCT03024996 | Terminated | Phase 3 | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy | January 3, 2017 | December 8, 2022 |
| NCT03737123 | Terminated | Phase 2 | Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | December 19, 2018 | May 18, 2022 |
| NCT03713944 | Terminated | Phase 2 | Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | November 15, 2018 | December 16, 2021 |
| NCT03292172 | Terminated | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | November 8, 2017 | February 26, 2019 |
| NCT03644823 | Terminated | Phase 2 | Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC | August 15, 2018 | December 31, 2020 |
| NCT03835949 | Unknown status | Phase 1 | Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer | July 16, 2019 | June 2022 |
| NCT03896074 | Unknown status | Phase 2 | Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) | May 2019 | April 2023 |
| NCT03673787 | Unknown status | Phase 1/Phase 2 | A Trial of Ipatasertib in Combination With Atezolizumab | August 13, 2018 | November 2023 |
| NCT03647956 | Unknown status | Phase 2 | Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors | October 1, 2018 | April 3, 2020 |
| NCT03620435 | Unknown status | Phase 2 | Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer | May 1, 2018 | December 30, 2020 |
| NCT04696939 | Unknown status | Phase 2 | Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients | January 2021 | October 2023 |
| NCT03448835 | Unknown status | Phase 2 | Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) | March 7, 2018 | January 1, 2022 |
| NCT03340376 | Unknown status | Phase 2 | Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer | August 30, 2017 | September 2022 |
| NCT03616691 | Unknown status | Phase 2 | Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC | August 1, 2018 | June 30, 2020 |
| NCT03498222 | Withdrawn | Phase 1 | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin | June 1, 2018 | December 31, 2021 |
| NCT05327738 | Withdrawn | Phase 2 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma | December 10, 2022 | December 4, 2027 |
| NCT05935774 | Withdrawn | Phase 2 | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer | December 1, 2023 | July 31, 2028 |
| NCT05007769 | Withdrawn | Phase 2 | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC | October 31, 2021 | April 30, 2026 |
| NCT06090318 | Withdrawn | Phase 1/Phase 2 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | May 19, 2023 | May 30, 2023 |
| NCT05564416 | Withdrawn | Phase 2 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | October 12, 2023 | November 3, 2023 |
| NCT03818997 | Withdrawn | Phase 2 | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer | December 2019 | April 2022 |
| NCT04267237 | Withdrawn | Phase 2 | A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | March 31, 2021 | September 30, 2025 |
| NCT06006286 | Withdrawn | Phase 1/Phase 2 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | August 8, 2023 | November 10, 2023 |
| NCT03786419 | Withdrawn | Phase 2 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | August 2020 | August 2020 |
| NCT04510584 | Withdrawn | Phase 2 | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | July 16, 2021 | February 22, 2023 |
| NCT04249167 | Withdrawn | Early Phase 1 | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | January 23, 2020 | November 17, 2021 |
| NCT03340558 | Withdrawn | Phase 2 | Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer | May 2018 | February 2025 |
| NCT03369964 | Withdrawn | Phase 1 | A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | March 14, 2018 | August 31, 2019 |
| NCT04989283 | Withdrawn | Phase 2 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | September 9, 2021 | May 10, 2031 |
| NCT03693573 | Withdrawn | Phase 3 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma | January 11, 2019 | January 31, 2024 |
| NCT04611776 | Withdrawn | Phase 2 | A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer | July 1, 2021 | January 8, 2026 |
| NCT03973879 | Withdrawn | Phase 1/Phase 2 | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | February 2020 | January 2024 |
| NCT05510427 | Withdrawn | Phase 1 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | August 7, 2023 | August 7, 2023 |
| NCT04630210 | Withdrawn | Early Phase 1 | Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity | February 2021 | January 31, 2025 |
| NCT05238831 | Withdrawn | Early Phase 1 | SMMART Adaptive Clinical Treatment (ACT) Trial | January 30, 2023 | May 31, 2026 |